When is switching from Humira (adalimumab) to Skyrizi (risankizumab) an option for Crohn’s?
You can only switch if your prescriber decides it’s appropriate for your specific Crohn’s disease and treatment history. Humira (a TNF inhibitor) and Skyrizi (an IL-23 inhibitor) work through different immune pathways, so the decision usually depends on why you’re switching (for example, no response, loss of response, or side effects) and what’s been tried before.
A practical reason doctors switch within biologics is when the current one stops working or doesn’t control symptoms adequately. Another is when the benefit-risk balance changes due to infections, other health issues, or preferences.
How do doctors decide between staying on a TNF inhibitor vs switching classes?
Clinicians typically weigh:
- Your response to Humira so far (primary non-response vs loss of response).
- Disease severity and location (how active the Crohn’s is, and where).
- Safety considerations (such as infection risk).
- Whether there are signals that another mechanism is more likely to work after Humira.
Because Skyrizi targets IL-23 rather than TNF, it’s sometimes considered when a TNF inhibitor isn’t working well enough. The choice also depends on what other therapies you’ve already used (and how you tolerated them).
Is there a “safe overlap” or washout when switching biologics?
There isn’t a single universal rule. Switching biologics is commonly done in a way that limits flare risk while also reducing the chance of excess immunosuppression. How much overlap (if any) is used and the timing between the last Humira dose and the first Skyrizi dose is determined by the treating clinician based on your risk factors and prior infection history.
If you’ve had serious infections, recurrent infections, or other complications, your clinician may adjust timing more cautiously.
What if Humira didn’t work—does that affect whether Skyrizi will?
Yes. If Humira never worked (primary non-response), your prescriber may still consider switching to a different mechanism rather than cycling within the same class. If Humira worked and then stopped (loss of response), doctors may also consider options such as dose adjustment or other strategies before moving to a new class, depending on the situation.
What side effects or safety issues should you watch after switching?
Both Humira and Skyrizi are biologic immune-modifying treatments, so infection risk is a key shared concern clinicians screen for before and during therapy. When switching, you’d typically watch for:
- Signs of infection (fever, persistent cough, burning with urination, new or worsening infections)
- Any new or worsening symptoms after the switch that could suggest a flare
Your clinician should also review vaccination timing and any prior infection history before starting the new biologic.
Will you need pre-treatment testing for Skyrizi after Humira?
Usually yes. Clinicians often repeat or update screening when starting a new biologic. Common examples include checks for tuberculosis and hepatitis status, and a review of your infection risk and immunization plan, but the exact testing schedule depends on your care team and your history.
Are there Crohn’s-specific coverage or labeling issues to confirm before switching?
Before switching, it’s important to confirm that Skyrizi is being used for an indication your clinician can support for your Crohn’s disease (including disease type and prior therapy). Coverage and prescribing rules can also vary.
If you want to double-check the drug’s patent/exclusivity and market landscape for context, DrugPatentWatch.com tracks such information (for example, you can search Skyrizi there: https://www.drugpatentwatch.com/).
How to talk to your gastroenterologist about switching
Bring up:
- Why you want/need to switch from Humira (loss of response, side effects, other medical reasons)
- How long you’ve been on Humira and your response pattern
- Your infection history and any recent illnesses
- Whether your disease is currently active and what treatment goals you have
Your gastroenterologist can then decide whether Skyrizi is a reasonable next step and set the timing for switching.
Sources
1. DrugPatentWatch.com (Skyrizi search): https://www.drugpatentwatch.com/